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Abstract
Lucanthone and hycanthone are thioxanthenone DNA intercalators used in the 1980s as antitumor agents. Lucanthone is in
Phase I clinical trial, whereas hycanthone was pulled out of Phase II trials. Their potential mechanism of action includes DNA
intercalation, inhibition of nucleic acid biosyntheses, and inhibition of enzymes like topoisomerases and the dual function
base excision repair enzyme apurinic endonuclease 1 (APE1). Lucanthone inhibits the endonuclease activity of APE1,
without affecting its redox activity. Our goal was to decipher the precise mechanism of APE1 inhibition as a prerequisite
towards development of improved therapeutics that can counteract higher APE1 activity often seen in tumors. The IC50
values for inhibition of APE1 incision of depurinated plasmid DNA by lucanthone and hycanthone were 5 mM and 80 nM,
respectively. The KD values (affinity constants) for APE1, as determined by BIACORE binding studies, were 89 nM for
lucanthone/10 nM for hycanthone. APE1 structures reveal a hydrophobic pocket where hydrophobic small molecules like
thioxanthenones can bind, and our modeling studies confirmed such docking. Circular dichroism spectra uncovered change
in the helical structure of APE1 in the presence of lucanthone/hycanthone, and notably, this effect was decreased
(Phe266Ala or Phe266Cys or Trp280Leu) or abolished (Phe266Ala/Trp280Ala) when hydrophobic site mutants were
employed. Reduced inhibition by lucanthone of the diminished endonuclease activity of hydrophobic mutant proteins (as
compared to wild type APE1) supports that binding of lucanthone to the hydrophobic pocket dictates APE1 inhibition. The
DNA binding capacity of APE1 was marginally inhibited by lucanthone, and not at all by hycanthone, supporting our
hypothesis that thioxanthenones inhibit APE1, predominantly, by direct interaction. Finally, lucanthone-induced
degradation was drastically reduced in the presence of short and long lived free radical scavengers, e.g., TRIS and DMSO,
suggesting that the mechanism of APE1 breakdown may involve free radical-induced peptide bond cleavage.
Citation: Naidu MD, Agarwal R, Pena LA, Cunha L, Mezei M, et al. (2011) Lucanthone and Its Derivative Hycanthone Inhibit Apurinic Endonuclease-1 (APE1) by
Direct Protein Binding. PLoS ONE 6(9): e23679. doi:10.1371/journal.pone.0023679
Editor: Fernando Rodrigues-Lima, University Paris Diderot-Paris 7, France
Received September 24, 2010; Accepted July 23, 2011; Published September 15, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by DOE grant KP-1401020/MO-079, NIH grant R01-CA86897, the Intramural Research Program of the National Institute on
Aging and the Intramural Research Program of the NIH, National Institutes of Environmental Health Sciences (Z01ES050158 & Z01-ES050159). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mnaidu@bnl.gov
Introduction
APE1 (also termed Ref-1, APEX, HAP1, AP endo) is a
multifunctional protein with distinct activities assigned to different
parts of its structure. The N-terminal region is responsible for its
redox function, whereas the endonuclease activity is mediated by
the larger C-terminal portion [1–3]. APE1 is abundant in human
cells and accounts for nearly all of the apurinic/apyrimidinic (AP)
site cleavage activity found in cellular extracts [4]. APE1 has a
strong Mg2+ -dependent AP endonuclease activity, a 39-phospho-
diesterase activity, a 39-mismatch exonuclease activity, and in
addition to its DNA repair functions, a redox activity whereby it can
reduce a conserved cysteine residue in a target transcription factor,
e.g. AP-1 (Jun/Fos), to activate cognate DNA binding. APE1 also
stimulates the sequence-specific DNA binding activities of HIFa,
NFkB, Pax5, Pax8, Myb and related activating transcription factor/
cAMP – responsive element binding proteins [5].
APE1 incision activity is altered in response to radiation and
chemotherapy in medulloblastoma and primitive neuroectodermal
tumors [6]. Silber et al. also showed that APE1 repair activity,
which is increased by oxidative stress, contributes to resistance of
human glioma cells to alkylating agents [7]. Human glioma cell
lines that show lower APE1 expression were more sensitive to
methyl methanesulfonate (MMS) and H2O2, known inducers of
AP sites and single strand breaks in DNA [8]. Robertson et al [9]
have shown that over-expression of APE1 in NT2 cells confers
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resistance to bleomycin and radiation. Recently, we demonstrated
a correlation between APE1 and radiation sensitivity with glioma
cell culture models [10]. When APE1 was over-expressed in U251
cells, they became more radioresistant contingent on the level of
APE1 over-expression, whereas siRNA depletion of APE1 was
associated with radiation sensitivity. This correlation was reiter-
ated by recent studies where APE1 siRNA down-regulation in
either colorectal tumor cells in vitro or in a subcutaneous nude
mouse colon cancer model enhanced radiosensitivity as revealed
by increased apoptosis [11]. In addition to the siRNA studies, we
modulated APE1 repair nuclease function using two of its known
small molecule inhibitors, lucanthone (1-[2-diethylaminoethyla-
mino]-4-methylthioxanthen-9-one) [12] and CRT0044876 (7-
Nitroindole-2-carboxylic acid) [13], and showed that APE1
inhibition resulted in increased radiosensitivity.
Due to the dual function of APE1, several inhibitors are being
discovered which selectively inhibit either its DNA repair or redox
function. The DNA repair inhibitors include the indirect inhibitor
methoxamine (MX) [5,14] and the direct/indirect inhibitors such
as lucanthone and CRT0044876. The redox function (Ref-1)
inhibitors are soy isoflavones [15], E3330 [16–17] and its
benzoquinone and naphthoquinone analogues [18], PRNI-299
[19], BQP [20] and resveratrol [21]. Thus, recent efforts have
focused on the potential to strategically regulate APE1 protein
activity in cells, possibly through the use of small molecular
inhibitors, as a means of improving therapeutic agent response.
Lucanthone (CAS479-50-5) and hycanthone (CAS3105-97-3)
belong to a family of thioxanthenones and were originally
synthesized for use as anti-schistosomal drugs. They were also
determined to be DNA intercalators, and like actinomycin D,
inhibited RNA synthesis as well as the DNA processing enzymes
topoisomerases I and II [22]. The effects of lucanthone are
thought to be mediated by its bioactive metabolite, hycanthone
[23]. Hycanthone was shown to be a better anti-schistosomal [24]
agent than lucanthone. However, due to the negative side effects of
hycanthone, including acute hepatic necrosis [25], strong
mutagenicity [26] and weak carcinogenicity [27], the use of
hycanthone for treatment of human schistosomiasis has been
discontinued. Lucanthone, on the other hand, has been used to
treat schistosomiasis for almost 20 years before being replaced by
new drugs. Work by Turner et al [28] showed that radiolabeled
lucanthone was more concentrated in neoplastic tissue relative to
the surrounding muscle and skin. Since lucanthone is able to cross
the blood brain barrier and inhibit cell proliferation without
affecting normal non-cycling cells, the compound has been used as
an adjuvant for brain tumor radiotherapy [29] and is currently in
clinical trial.
Lucanthone is known to inhibit APE1 AP endonuclease activity,
without affecting its redox function [12]. Lucanthone is also
known to promote accumulation of AP sites in HeLa cells [30],
lesions that are substrates for APE1. Since Bailly et al [31] showed
that both lucanthone and hycanthone preferentially intercalate at
AT-rich sequences in DNA, APE1 may be prevented from
accessing the AP site due to the presence of DNA-bound
lucanthone/hycanthone. Alternatively, lucanthone may elicit its
inhibitory effect on APE1 incision activity via direct binding to the
protein. As previously reported APE1 structures (PDB ID: 2ISI,
1DEW and 1DE9) show the presence of a hydrophobic site lined
by Phe266, Trp280 and Leu282, overlapping the active site of the
protein, we hypothesized that hydrophobic molecules like
lucanthone/hycanthone would bind at these residues. In addition,
based on past evidence [32], we postulated that lucanthone/
hycanthone may induce protein oxidation due to the binding
capacity and other features of the compound. Data are presented
here in support of the idea that lucanthone and its structural
analogue hycanthone show very little, if any, inhibition of the
DNA (depurinated) binding capacity of APE1 and can indeed
predominantly inhibit APE1 endonuclease activity by direct
binding to the hydrophobic site and inducing cleavage of the
protein via oxidative damage.
Materials and Methods
Reagents
The U251-MG glioblastoma multiforme (GBM) cell line was a
kind gift from Dr. Dennis Deen of UCSF. These cells were
maintained in Eagle’s Minimal Essential Medium with 2 mM L-
glutamine and 1.5 g/L sodium bicarbonate, supplemented with
10% fetal bovine serum (FBS), and sub-cultured twice a week (1:3).
Cell culture media and FBS were obtained from Invitrogen
(Carlsbad, CA). APE1 protein was detected using polyclonal anti-
APE1 (Santa Cruz Biotechnology, Santa Cruz, CA) and tubulin
was detected using polyclonal anti--tubulin (Sigma-Aldrich, St.
Louis, MO). ECL kit from Invitrogen has anti-mouse and anti-
rabbit –HRP conjugated secondary antibodes which were used at
1: 30,000 dilution. Lucanthone and hycanthone (Figure S1)
obtained (in 1970s by Michael Waring) from Dr S. Archer,
Sterling-Winthrop Research Institute, Rensselaer, NY, were
maintained at 4C under hygroscopic conditions, and were
dissolved in sterile double distilled water just prior to reactions.
Plasmids consisting of full length APE-1 in pET15b and pCMV10
were kind gifts from Dr. T. Izumi and Dr. Hua Fung, of Louisiana
State Health Center, New Orleans, LA and Harvard Medical
School, Boston, respectively.
Cells extract preparation
0.5–1.56106 cells were resuspended in 200 ml of ice-cold 16cell
extraction buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA,
100 mM NaCl and 1 mM PMSF) and sonicated for 5–10 s in a
4uC bath sonicator (Sonifier Cell Disruptor, Plainview, NY) at a
setting of 20 mHz. The sonicates were centrifuged at 10,000 rpm
for 5 min at 4uC. Soluble and insoluble fractions were collected
(the insoluble pellet was resuspended in 200 ml of cell extraction
buffer) and assayed for APE1 protein and enzyme activity as
described below.
Expression and purification of full length APE1
E.coli BL21/DE3 were transformed with the pET15b plasmid
containing full length APE1 and these bacterial cultures (500 ml
YTB medium) were grown to OD600 of 0.6 and the full length
APE1 protein was successfully expressed and purified to 25–30 mg
protein/L (20 mM HEPES, 200 mM NaCl buffer pH 7.5) culture
according to method of Agarwal et al [33]. Additional stocks of
wild-type, full length APE1, and the APE1 mutant proteins (e.g.
F266A), were generated as described [34]. A pCMV-APE1
plasmid [19] was transfected into U251 cells using Lipofectamine
2000 as per manufacturer’s instructions followed by selection in
G418 as detailed in our recent paper [10] and clones selected for
APE1 overexpression.
SDS-PAGE and Western blot
Total purified protein concentration was determined by the
ratio of A280/A260. 250 ng of APE1 treated with lucanthone or
hycanthone (0.05–100 mM) for 2 h at 37uC in final volume of
30 ml were mixed with an equal volume of gel loading buffer
(0.001% bromophenol blue, 4% SDS, 10% 2-ME, 20% glycerol,
and 125 mM Tris pH 6.8) and denatured at 95uC for 5 min.
Total protein concentration in cell extracts was determined using
Thioxanthenones Inhibit APE1
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the Bradford assay (BioRad, Hercules, CA) and 25 mg of total
protein from soluble or insoluble cell fractions were mixed with an
equal volume of gel loading buffer (0.001% bromophenol blue,
4% SDS, 10% 2-ME, 20% glycerol, and 125 mM Tris pH 6.8)
and denatured at 95uC for 5 min. This mixture was separated by
SDS-PAGE (4% stacking, 7.5% resolving gel) for 2–3 h at 40 mA
on a BioRad MiniPROTEAN II Electrophoresis Cell. To detect
proteins, proteins were transferred onto a trans-Blot nitrocellulose
membrane (0.45 mm; BioRad) overnight at 4uC at 15 mA in
standard Tris-Glycine buffer containing 20% ethanol. Membranes
were probed using polyclonal anti-APE1 or polyclonal anti--
tubulin at 1/1,000 dilution in TTBS (0.1% Tween 20 in TBS
(pH 7.5)) with secondary, anti-rabbit HRP-conjugated antibody
used at 1/30,000 dilution to detect APE1 and -tubulin protein
control. Chemi-luminescence was developed using an ECL kit
according to the manufacturer’s instructions and detected by
exposing the blot to HyperfilmECL for 30 s–3 min. (GE
Healthcare Biosciences, Piscataway, NJ).
APE1 Endonuclease activity
APE1 endonuclease activity was determined using an assay that
measures the conversion of plasmid DNA from supercoiled to
relaxed form by incision at an abasic site [35–36]. Briefly, the
substrate used was 200 ng of depurinated pUC18 DNA in 10 ml of
16APE1 buffer containing 50 mM Hepes, pH 7.4, 150 mM KCl,
5 mM MgCl2 and 100 mg/ml of BSA in presence of different
concentrations of the cell extract (1 ml containing 0–55 ng of total
protein). Similar reactions mixtures were set up with untreated
pUC18, which served as the internal control. This reaction
mixture was incubated at 37uC for 15 min, and the reaction was
stopped by addition of alkaline stop mix (0.25% bromocresol
green in 0.25N NaOH, 50% glycerol) and left at room
temperature for 10–15 min. Then the products were resolved on
a 0.8% agarose gel in 40 mM Tris-acetate and 2 mM EDTA for
2 h. The gel was stained with ethidium bromide to visualize
supercoiled and relaxed plasmid DNA and imaged with a digital
imaging system [37] and the area under the supercoiled and
relaxed form was determined. Final calculations were done in
femtomoles (fmol) of abasic sites incised/min/mg protein with
normalization done using Pyruvate Kinase units (PKU) present in
these extracts. Poisson distribution calculations were done on
supercoiled and relaxed bands to estimate incisions per plasmid
molecule and the resulting depurinated pUC18 had 1 AP site per
molecule. The endonuclease activity inhibition by lucanthone was
analyzed using standard Lineweaver-Burke Plot to determine if the
inhibition was competitive or non-competitive.
Cleavage of APE1 by lucanthone and CRT0044876
Western blotting was carried out by 7.5% SDS-PAGE of cell
extracts (20 mg total protein per lane) either from APE1
overexpresser clone 5 pretreated with 2.5–200 mM concentration
of lucanthone/CRT0044876 or recombinant APE1 for 2 h at
37uC in presence of protease inhibitor cocktail (2 tablets (Roche,#
11836153001) containing mixture of several protease inhibitors
with broad inhibitory specificity for serine, cysteine and metallo-
proteases in all systems, dissolved in 20 ml of APE1 buffer).
CRT0044876 was used as another APE1 small molecule inhibitor
with possible direct interaction between itself and APE1 [13].
Pretreatment of Ape1 overexpressor clone 5 cultures with 10 mg/
ml of cycloheximide (CHX) for 4 h prior to lucanthone/
hycanthone addition, was carried out to determine if these
thioxanthenones affected Ape1 protein synthesis. Radioquenchers
like 10 mM TRIS, ascorbic acid (100 mM), N-acetyl cysteine
(100 mM) (with recombinant APE1) or 1% DMSO (with cell
extracts) were used to inhibit the cleavage reactions.
Direct binding of APE1 to lucanthone/hycanthone
APE1 (and its hydrophobic mutants) and lucanthone/hycan-
thone reaction stoichiometry was studied using surface plasmon
resonance on a BIACORE 2000 apparatus (Biacore, GE
Healthcare, Sweden) at the protein core facility in SUNYSB, to
determine the affinity of the two drugs for APE1 (or ND40 APE1).
APE1 and its mutants (10 mg) (RUmax values were 9000 RU units
after immobilization) were immobilized on a CM5 chip by amine
coupling (as per the manufacturer’s instructions) and binding
experiments were performed at 20uC in 10 mM HBS-EP buffer,
pH 7.4. Lucanthone (or hycanthone) (20–700 mM) was injected as
analyte over the sensor chip in HBS-EP buffer at 10 ml/min. The
regeneration was achieved by 10 mM glycine-HCl, pH 3.0
between each analyte (drug) concentration.
Circular Dichroism
APE1 and its mutant proteins (10 mg/ml), 50 ml (500 mg)
(14 mM) in APE1 buffer (50 mM HEPES, pH 7.4, 150 mM KCl,
5 mM MgCl2), were mixed with lucanthone/hycanthone (1 mg/
ml), 50 ml (50 mg), 140 mM and incubated at 37uC for 60 min and
far UV-CD spectra were recorded at NSLS U11 beam line at
BNL. Lucanthone and hycanthone were also scanned as drug
controls. The scanning parameters used were a 0.001 cm path
length quartz cell, scanning wavelengths from 260 to 170 nm,
bandwidth of 0.5 nm, digital integration time of 1 s, time constant
of 200 ms, step size of 1 nm, and sensitivity of 200 mV. The data
were corrected with blank subtraction from APE1 buffer alone.
The secondary structure for APE1 with or without lucanthone or
hycanthone was analyzed using CDSSTR program DICHRO-
WEB [38].
MALDI-TOF
100 nM of APE1 protein was treated with 100 mM of
lucanthone, hycanthone or CRT at 37uC for 2 h and 24 h and
analyzed on sinipinic acid matrix on a Voyager-DE STR (Applied
Biosystems) MALDI-TOF instrument at the Proteomics facility at
SUNYSB in a linear mode.
Ape1 fragment identification by MALDI-TOF and LC/MS
The full length APE1 and its 25 kDa fragment were digested in
gel by trypsin and analyzed by MALDI-TOF and LC/MS.
Voyager-DE STR (Applied Biosystems) MALDI-TOF instrument
at the Proteomics facility at SUNYSB in a reflector mode was used
and the matrix was Alpha-cyano-4-hydoxycinnamic Acid (CHCA).
Docking studies
The screening used the AutoDock suite of programs [39–41].
The screening was driven by a set of scripts described in Mezei et al
[42]. Models of lucanthone and hycanthone were generated with
Marvin Sketch (figure S1) (ChemAxon, Budapest, Hungary), and
the structures optimized with the semiempirical AM1 method, as
implemented in Gaussian-03 [REF_G] – the script set referred to
above includes utilities to create the Gaussian input and the
extraction of the optimized coordinates. The terminal amine was
protonated, as determined previously and the overall structures
were in good agreement with the X-ray structure of hycanthone
[43]. The protein structure was obtained from the Protein Data
Bank (PDB ID: 2ISI). Assignment of atom types, and partial charges
(using Gasteiger –Marsili method) and merging of non-polar
hydrogens with their carbons was performed with AutoDockTools
Thioxanthenones Inhibit APE1
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e23679
(http://mgltools.scripps.edu/downloads). The generation of the
energy grids, the preparation of ligand files for docking and the
actual docking was driven by a script that keeps a user-defined
number of docking jobs running on different processors of our SGI
cluster [42].
Dockings were based on a 1266106*126 grid, with grid spacing
of 0.375 A˚ that targeted the hydrophobic pocket lined by
hydrophobic amino acids Trp280, Phe266 and Leu282. The
minimization resulting in docked poses was performed using
Lamarckian genetic algorithm (LGA) and pseudo-Solis and Wets
method. Each LGA job consisted of 200 runs with 270, 000
generations in each run and maximum number of energy
evaluations of 2,000,000. After clustering of the docked poses by
Autodock the program Dockres (URL: http://inka.mssm.edu/
,mezei/dockres) sorted cluster representatives of the docked poses
and extracted the list and coordinates of the top-scoring ones in
complex with the target protein.
Molecular dynamics (MD) simulations
The docking top-scoring poses APE1-lucanthone and APEI-
hycanthone were solvated, using VMD [44], in a water box
extending 10 A˚ beyond the edge of the complex in all directions,
using the TIP3P water model [45]. The system was neutralized
with chloride ions and consisted of a total of ,36,100 atoms. MD
calculations were performed with NAMD [46] using the
AMBER99SB force field [47]. The ligand parameters were
determined with ANTECHAMBER [48] using the General
Amber Force Field (gaff) [49]. Partial atomic charges were
determined with the AM1-BCC method. The systems were
energy minimized with 10,000 steps of conjugate gradient energy
minimization, followed by gradual heating from 0 to 310 K in
30 ps, and then maintained at constant temperature and pressure
(1.01325 bar). The simulations were carried with periodic box
conditions, with a 2 femptosecond time step, a uniform dielectric
constant of 1, a 1–4 scaling value of 0.833333, a cutoff of non-
bonded forces with a switching function starting at 10 A˚ and
reaching 0 at 12 A˚, PME with a tolerance of 1026, and all bonds
involving hydrogens constrained with the SHAKE algorithm. A
production run was performed for 30 ns and the trajectories were
analyzed with VMD.
EMSA assay
In order to elucidate whether lucanthone and hycanthone could
inhibit APE1 by interfering with APE1-DNA interaction through
their DNA intercalation ability, we measured the DNA binding
capacity of APE1 in the presence of lucanthone and hycanthone
by incubating different concentrations of APE1 (10 nM and
25 nM) with 100 mM of lucanthone and/or hycanthone for
30 min and subsequently incubating the mixture with 25 nM of
THF-containing substrate at 25uC in binding buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl, 0.1 mg/ml BSA, 0.5 mM
EDTA and 1 mM DTT) for 30 min. THF stands for tetrahydro-
furan that represents a synthetic abasic site. This is commonly
inserted into an oligonucleotide substrate for measuring APE1
cleavage activity. 59-incision of THF by APE1 results in a residue
that mimics reduced 59-deoxyribose phosphate group. Since THF
group lacks the 19-OH group, it blocks b-elimination that is
required for mediating any dRP lyase activity. The sequence of the
APE1 substrate with THF group is 59CTGCAGCT-
GATGCGCFGTGCGGATCCGGTGC-39 as described by Liu
et al [50].
APE1-DNA complex was then separated from unbound
substrate DNA by electrophoresis under native conditions in a
1% agarose-0.1% acrylamide gel at 4uC for 1.5 h as described
previously [50–51].
Results
Lucanthone/hycanthone promotes APE1 cleavage
Previously, we created an APE1 overexpressor glioma cell line,
the U251 1–5 clone [52], to determine the contribution of APE1
to radio-resistance. Since past studies had shown that lucanthone
inhibits DNA and RNA synthesis [53] [54] with or without
affecting protein synthesis [53], we determined the effect of
lucanthone on APE1 protein expression in the U251 1–5 APE1
overexpressor cell line pre-treated with 10 mg/ml cycloheximide
(CHX) (a protein synthesis inhibitor) for 4 h. We found that de
novo APE1 synthesis was not affected significantly, as seen by the
near normal levels of intact APE1 in CHX treated cells (Figure 1).
However, lucanthone and hycanthone were found to induce
cleavage of APE1 as seen by the formation of a 25 kDa fragment.
To begin to define the mechanism of cleavage, we treated whole
cell extracts from the U251 1–5 APE1 overexpressor clone with
increasing concentrations of lucanthone (2.5–100 mM) and
examined APE1 protein stability in the presence of a protease
inhibitor cocktail. We found that lucanthone at 50 and 100 mM
caused APE1 cleavage and/or degradation as evidenced by a
decrease in the full-length 35.5 kDa fragment and an increase in a
,25 kDa fragment (Figure 2). These data suggested a direct effect
of lucanthone on APE1 protein integrity, as effects on gene
expression are not relevant in this paradigm. It is highly unlikely
that the drug preparation was contaminated with a protease, as the
compound was synthesized by organic methods de novo and
handled to avoid any protease contamination. In addition, we
found no evidence of non-specific degradation of other control
proteins, such as tubulin and human NTH1 (human Nth was used
as a DNA repair enzyme control, since like APE1, human Nth has
a disordered N-terminus; data not shown).
Figure 1. Lucanthone/Hycanthone promotes APE1 cleavage in
presence of CHX and this cleavage is inhibited by 1% DMSO.
Western blot of total cell extract from APE1-5 overexpresser clone
pretreated with 10 mg/ml of cycloheximide for 4 h followed by 25–
100 mM lucanthone/hycanthone for 2 h (12.5 mg of total cell protein
loaded per lane).
doi:10.1371/journal.pone.0023679.g001
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We next determined the effect of lucanthone, as well as CRT, a
commercially available APE1 inhibitor modeled to bind at the
hydrophobic site of the protein [13], on the stability of APE1 and
tubulin in the presence of a protease inhibitor cocktail. As shown
in Figure 3, we found that lucanthone caused cleavage of APE1 at
50 mM in U251 1–5 whole cell extracts, whereas for similar
cleavage to occur with CRT, we needed to use 200 mM of the
inhibitor. The tubulin protein was unaffected by lucanthone, but
showed some shift in its migration at 200 mM CRT.
Recombinant full length APE1 is also cleaved by
lucanthone
To further delineate the mechanism of lucanthone-induced
cleavage, studies were performed with recombinant full length
APE1 protein. When the recombinant protein was treated with
10–50 mM lucanthone at 37uC for 2 h, we observed an increase in
the formation of the 25 kDa fragment and a corresponding
decrease in AP endonuclease activity (Figure 4A and 4B). When
we studied the kinetics of inhibition shown by lucanthone, we
found that lucanthone appeared most likely to be a non-
competitive inhibitor of APE1 (Figure 4B). When human Nth
was treated with lucanthone, we did not observe any cleavage
(data not shown), indicating specificity for APE1. These data imply
that lucanthone directly binds to APE1.
As we observed that lucanthone/hycanthone induced cleavage
of APE1, we determined if this cleavage might be due to oxida-
tive damage of the peptide bonds in the protein. We therefore per-
formed an experiment in the presence of the short and long lived
radical quenchers: 10 mM (final) tris(hydroxymethyl)aminomethane
(TRIS), 100 mM ascorbic acid or 100 mM N-acetyl cysteine (for
purified APE1 protein) and 1% DMSO (for APE1 protein from
overexpressor cell extracts), and found that lucanthone-induced
cleavage of APE1 was significantly inhibited (Figure 5 and Figure 6).
As lucanthone is made of a strong hydrogen bonding acid, a
Figure 2. Lucanthone promotes APE1 cleavage in presence of protease inhibitor. Western blot of APE1 over expresser clone 5 pretreated
with increasing (2.5–100 mM) concentration of lucanthone in presence of protease inhibitor cocktail for 2 h at 37uC (10 mg of total cell protein loaded
per lane). An arrow indicates the corresponding increase in APE1 25 kDa fragment in last two lanes with a decrease in 35.5 kDa APE1 protein.
doi:10.1371/journal.pone.0023679.g002
Figure 3. Lucanthone/Hycanthone promote APE1 cleavage at
lower concentration than CRT. Western blot of APE1 over expresser
clone 5 pretreated with increasing concentration of lucanthone (2.5–
100 mM) and CRT0044876 (2.5–200 mM) in presence of protease
inhibitor cocktail for 2 h at 37uC (10 mg of total cell protein loaded
per lane). The corresponding decrease in 35.5 kDa APE1 protein band
and increase in 25-kDa-degradation product is indicated by the arrows.
doi:10.1371/journal.pone.0023679.g003
Figure 4. Lucanthone promotes APE1 cleavage in vitro by
possible non-competitive binding. A. Recombinant APE1 protein
(250 ng) treated with 10–50 mM lucanthone at 37uC for 2 h, the
numbers in italic font represent fold change in APE1 and its 25 kDa
fragment as measured by area analysis using Image J quantification
program. B. Lineweaver-Burke plot for endonuclease assay determina-
tions as detailed in Materials and Methods. Units of 1/v were min/
fmoles of abasic sites incised and for 1/[S] was inverse of nM of
depurinated plasmid DNA.
doi:10.1371/journal.pone.0023679.g004
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secondary amine and two proton bonding bases (the carbonyl and
tertiary amine substituent) and is known to possess a strong
intramolecular amino carbonyl hydrogen bond [32], which can
possibly attack the amide linkage in APE1, this may be one of the
ways it can affect APE1 integrity.
APE1 directly interacts with lucanthone and hycanthone
CD spectral studies revealed considerable conformational
changes in APE1 in the presence of either lucanthone or
hycanthone, indicating a direct physical interaction between the
protein and small molecule (Figure 7). In particular, a significant
change in the helical portion of the protein was evident, as seen by
a decrease in the average helical length per segment (Table 1).
To further characterize the apparent molecular interaction
between APE1 and lucanthone/hycanthone, direct binding studies
were undertaken using measurements of surface plasmon reso-
nance relative response units (RU) on a BIACORE 2000, which
can determine the binding constant, as well as the rates and the
stoichiometry of the reaction [48]. In these experiments, a very
good binding response was observed between APE1 and
hycanthone (Figure 8, top), with weaker binding to lucanthone
(Figure 8, bottom). The association phase was weak for lucanthone
(see Figure 8, bottom and Table 2), whereas for hycanthone there
was a much stronger association, with the ka and kd of full length
APE1 being about 10-fold higher and 100-fold lower, respectively,
for hycanthone. The spike in RU value seen with lucanthone may
be due to the initial injection coupled with poor binding, which
causes an uneven plateau formation (these seen also figure S2);
when higher concentration was used, a clear plateau was seen
(figure S2). The negative values seen for lower concentrations of
lucanthone are most probably due to very poor interaction of
lucanthone with APE1 under BIACORE binding conditions,
which when compared to buffer control resulted in no surface
plasmon resonance. As the drugs were dissolved in distilled water,
we did not see any precipitation until 1 mM. The APE1:
lucanthone/hycanthone stochiometry appeared to be close to 1
for hycanthone, but may have been lower for lucanthone. ‘‘r’’
versus Cfree plot was done to determine the differences in affinity
of lucanthone and hycanthone and it was clear that hycanthone
had much higher binding affinity as compared to lucanthone.
Lucanthone Cleavage site identification with LC/MS
Preliminary data with sequence identification of APE1 protein
(sample 1) and its 25 kDa fragment (sample 3) found the cleavage
site to be between amino acid (aa) 53–63 resulting in about a
20 kDa fragment as shown in Figure 9. Peptide analysis of aa 64–
73 reveals that sample 3 begins at aa 64 and that this peptide is
about 100 times lower in concentration in sample 3. Peptide
analysis of aa 282–299 reveals that sample 3 ends after aa 299.
Peptide aa 53–63 is not present in sample 3. It appears that the
degraded protein (sample 3) has peptide present from aa 64 until
at least aa 299. Peptide aa 53–63 is not present, suggesting that the
cut/degradation is in the vicinity of aa 53–63. The precise N-
terminal sequence identification is needed to get the exact cleavage
site and studies are under way to determine that site.
Degradation of APE1 by lucanthone and hycanthone
MALDI TOF analysis was undertaken for samples analyzed
previously (SDS-PAGE/western blot; see earlier) to determine the
nature of the APE1 protein fragments in the presence of
lucanthone, hycanthone, or CRT at 37uC for 2 or 24 h. These
studies revealed steady degradation of APE1 into smaller
fragments (Figure 10) by lucanthone with time; the signal of the
parent 35.5 kDa peak was also significantly reduced, consistent
with APE1 breakdown. CRT treatment at the same concentration
resulted in much less cleavage of APE1, with the 35.5 kDa peak
remaining almost intact, particularly at 2 h, and only a couple of
smaller fragments of 10, 12 and 17 kDa appearing at 24 h.
Hycanthone showed cleavage of APE1 as evidenced mainly by 10,
11 and 17 kDa peaks, without the other smaller fragments seen
with lucanthone. By 24 h at 37uC, the full length APE1 peak was
almost completely degraded in the lucanthone/hycanthone
treated samples, whereas there was still an intact 35.5 kDa peak
with CRT (Figure 10). Even though we saw cleavage of
recombinant APE1, we did not see the 25 kDa fragment observed
Figure 5. Lucanthone promotes APE1 cleavage in vitro which is
inhibited by TRIS. Western blot of recombinant APE1 protein
(250 ng) treated with 10–50 mM lucanthone at 37uC for 2 h in absence
and presence of radical quencher, 10 mM Tris-HCl, pH 7.4.
doi:10.1371/journal.pone.0023679.g005
Figure 6. Thioxanthenones and CRT cleavage of APE1 is
inhibited by Ascorbic acid but not by N-Acetyl cysteine.
Western blot of recombinant APE1 protein (250 ng) treated with
100 mM of radical quenchers, NAC and Ascorbic acid and 100 mM of
lucanthone (L)/hycanthone (H) or 200 mM of CRT (C) at 37uC for 2 h.
doi:10.1371/journal.pone.0023679.g006
Figure 7. Lucanthone and hycanthone directly alter APE1
conformation. CD spectra of APE1 in presence of lucanthone and
hycanthone as described in materials and methods, which was analyzed
by Dichroweb program CDSSTR.
doi:10.1371/journal.pone.0023679.g007
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in the extract studies or recombinant protein experiments
described above (Figures 1 and 4). However, as we did see
fragments of 10–17 kDa on MALDI, it is possible that the 25 kDa
fragment degraded into these smaller fragments during the
analysis.
Molecular docking of lucanthone and hycanthone at the
hydrophobic site of APE1
To examine possible binding modes of lucanthone and
hycanthone with APE1, in silico molecular docking was performed
with the AutoDock suite of programs (Figure 11). To account for
the flexibility of structural elements and aa side chains, the top-
scoring pose of each ligand (based on the energy evaluation of
AutoDock and clustering of the poses) was fully solvated and
submitted to a 30 ns MD simulation. After an initial equilibration
in which the protein side chains and the ligand re-adjusted their
positions, the ligands were in a stable conformation for up to the
30 ns simulated, undergoing an average rmsd ,2 A˚ for the second
half of the simulation (data not shown). Overall, the docked
complexes of APE1-lucanthone and APE1-hycanthone superpose
with the MD simulated structures with an r.m.s.d. (root mean
square deviation) of 1.8 A˚/1.7 A˚ (Figure 12A and B). Lucanthone
binds deep in the hydrophobic pocket (Figure 12A), interacting
with the protein mainly via apolar contacts. The phenyl group of
lucanthone forms a parallel-displaced pi-stacking interaction to
Phe266, while the carbonyl group forms a transient hydrogen
bond with Thr268, with a average distance of 3.4 A˚ between
donor and acceptor throughout the simulation. The long flexible
side chain of the tertiary amine of lucanthone extended to the
DNA binding groove. The hycanthone binding site was shifted
towards the DNA binding groove and the unsubstituted ring was
buried in the hydrophobic pocket of the protein, in a position to
form a parallel pi-stacking interaction with Phe266. The hydroxyl
group of hycanthone formed a stable hydrogen bond with His309,
while the oxygen atom was stably coordinated with the APE1
bound magnesium cation (Figure 12B). The flexible side chain of
hycanthone extended into the solvent and made no protein
contacts.
Hydrophobic site mutants do not undergo dramatic
conformational changes in the presence of lucanthone
In light of the docking studies above, and since previous APE1
inhibitors (e.g. CRT and L-DOPA) were postulated to interact in
a similar manner with the protein [13,55], we determined
whether mutating a single hydrophobic site residue, Phe266 to
Ala/Cys (F266A or F266C), or mutating two hydrophobic
residues, Phe266Ala/Trp280Ala (F266A/W280A), would pre-
vent the lucanthone-induced conformational changes in APE1.
Bovine serum albumin (BSA) was included as a non-specific
protein control and the active site APE1 mutant Asp210Arg
(D210N) was included as a non-hydrophobic site control,
presenting the same binding ability but failing to cleave the
DNA. Human NTH1 and E.coli endonuclease IV (Nfo) were
used as other DNA repair enzyme controls. As shown in
Figure 13, lucanthone was able to induce conformational
changes in the wild type and D210N active site mutant APE1
proteins, but altered the hydrophobic site mutant protein F266A
or F266C to a lesser extent, while inducing almost no
conformational change in the double mutant F266A/W280A.
Lucanthone also caused little conformational changes on human
Nth and E.coli Nfo. These data indicate the importance of the
hydrophobic site residues F266 and W280 in binding the small
molecule inhibitor, and support the binding mechanism pro-
posed by molecular modeling.
Hydrophobic site mutants are not cleaved by lucanthone
and show lower inhibition of their endonuclease activity
in the presence of lucanthone
As we found that F266A, F266C or F266A/W280A proteins did
not undergo a significant conformational change in the presence of
lucanthone, we hypothesized that due to impaired binding,
lucanthone would show a lesser effect on protein cleavage and
endonuclease incision efficiency [34]. As seen in Figure 14A and
B, all the hydrophobic site mutants, except W280S, did not
undergo cleavage (this W280S mutant also showed conformational
change, figure S3), whereas the active site mutant D210N,
His309Ser (H309S) and His309Arg (H309N) were degraded. In
addition, lucanthone caused a corresponding inhibition of the
endonuclease activity of wild type, but no inhibition was detected
for the already reduced activity of the single mutants (F266A or
W280S), whereas the effect on endonuclease activity of the double
hydrophobic mutant’s endonuclease activity could not be detected,
as this double mutant (F266A/W280A) had very reduced activity
as reported earlier [56].
Lucanthone and hycanthone only marginally inhibit the
DNA binding capacity of APE1
As lucanthone and hycanthone are well known DNA inter-
calators, preferentially intercalating at AT rich sites in DNA, we
determined whether inhibition of APE1 endonuclease activity was
due to compound-DNA interactions, which may block APE1
access to the abasic substrate. The results from a gel mobility shift
assay demonstrated that both lucanthone and hycanthone, which
were pre-incubated with the protein prior to incubation with the
substrate DNA, only marginally inhibited or failed to inhibit APE1
DNA binding capacity as shown in Figure 15.
Table 1. Changes in APE1 conformation in presence of lucanthone and hycanthone.
Sample Helix 1 Helix 2
Av. helix length
per segment Strand 1 Strand 2
Av. strand length
per segment Turns Unordered
APE1 0.01 0.069 4.512 0.261 0.140 5.791 0.126 0.394
APE1 +Luc 0.00 0.071 4.053 0.262 0.140 5.762 0.125 0.403
APE1 +Hyc 0.00 0.069 4.020 0.267 0.141 5.799 0.124 0.399
Differences in CD conformation in presence of Lucanthone and Hycanthone. Data in Table 1 represent the CD analysis of APE1 in presence of lucanthone and
hycanthone (Figure 7) which are shown as changes in a helix, b sheet and unordered conformation of APE1 protein. APE1 protein (5 mg/ml), 50 ml (250 mg) in APE1
buffer (50 mM HEPES, 150 mM KCl, 5 mM MgCl2), was mixed with lucanthone/hycanthone (1 mg/ml), 50 ml (50 mg), incubated at 37uC for 60 min and far UV-CD spectra
were recorded at NSLS U11 beam line at BNL. These data are representation of three independent repeats.
doi:10.1371/journal.pone.0023679.t001
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Discussion
Our recent studies [10] showed that APE1 plays a significant
role in the survival of the glioblastoma cell line U87 as compared
to U251. Indeed, we found a direct correlation between the level
of APE1 expression and radio-resistance. In addition to our APE1
overexpressor studies with the radio-sensitive cell line U251, we
also showed that suppressing APE1 protein levels with the small
molecule inhibitor lucanthone caused radio-sensitization. Lucan-
thone was chosen as an APE1 inhibitor for several reasons: It is in
a Phase I clinical trial for tumor radiotherapy, its side effects are
almost negligible, and it can inhibit APE1 endonuclease activity
without affecting its redox function. However, as lucanthone has
good DNA intercalation ability, we hypothesized that the final
outcome of APE1 inhibition might be due to a fine balance
between direct and indirect effects. Thus, we sought to elucidate
the mechanism of APE1 endonuclease inhibition by lucanthone.
As APE1 has a well-characterized hydrophobic site within its
active site, we hypothesized those small hydrophobic molecules
like lucanthone may stack in this site through van der Waals
interactions and thus alter the active site causing repair
endonuclease inhibition. When we treated U251 1–5 glioma cells
with increasing concentrations of lucanthone, we observed a
concentration-dependent decrease in the normal 35.5 kDa APE1
protein band, along with an increase in a 25 kDa fragment. Since
this fragmentation was seen in the presence of protease inhibitors,
it is not likely the result of enzyme-mediated proteolysis, but may
occur due to a direct effect of lucanthone on the APE1 protein. We
reproduced the finding of lucanthone induced APE1 degradation
with purified recombinant protein, indicating that the cell
machinery was not required for the cleavage event. MALDI
TOF analysis of APE1 protein treated with lucanthone or
hycanthone revealed a significant degradation of the 35.5 kDa
peak and lower molecular weight species, although the 25 kDa
fragment could not be found. This observation may suggest that
the 25 kDa fragment is further degraded into smaller fragments.
Sequencing of the 25 kDa APE1 fragment by MALDI TOF
indicated the approximate cleavage site to be between aa 53–63.
Our finding that short and long lived free radical quenchers, such
as TRIS, ascorbic acid and DMSO, inhibit this degradation
implies that protein fragmentation may be facilitated through a
Figure 8. APE1 binds directly with lucanthone and hycanthone
with different affinities. APE1 protein (100 mg) (ligand) was
immobilized on carboxymethyl-5 (CM-5) chip by amine coupling
according to manufacturer’s instructions. Hycanthone (top figure)
(analyte) and lucanthone (analyte) (lower figure) (analyte) at different
concentrations (as shown as numbers representing mM values) were
tested for binding to APE1 on BAICORE 2000 SPR measurement system
available at SUNYSB proteomics core facility. The observed maximum
response (RU) was determined by direct curve fitting of the obtained
data assuming a 1:1 interaction model. The third sub figure shows plot
of r (RU/RUmax) versus Cfree. Binding studies were carried out 3 times
and data presented are representative of those 3 separate experiments.
doi:10.1371/journal.pone.0023679.g008
Table 2. Kinetics of lucanthone and hycanthone binding to
APE1.
Inhibitor Conc (mM) RUligand RUmax ka (1/Ms) kd (1/s) KD (nM)
LUC 20 282 91 878 7.7661025 89
40 226
80 2.5
160 77
320 94
640 62
HYC 22 24 90 90 8.961027 10
44 45
88 78
176 79
352 90
704 118
Hycanthone shows higher binding affinity as compared to Lucanthone. Data in
Table 1 show affinity analysis of lucanthone (LUC) and hycanthone (HYC)
binding to APE1 immobilized on CM5 chip (Figure 6A and 6B) using
BIAsimulation software available at the Biacore facility at SUNYSB.
RU = Resonance units are measure of changes in refractive index;
ka = association constant; kd = dissociation constant and KD = Affinity constant.
These data are representation of two independent repeats.
doi:10.1371/journal.pone.0023679.t002
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free radical mediated peptide bond cleavage reaction. The lack of
inhibition of this cleavage by N-acetyl cysteine may indicate that a
higher concentration of this free radical quencher may be needed
or that thioxanthenones are able to render this quencher
ineffective.
Our molecular docking, biochemical and biophysical studies,
including those using various hydrophobic site and active site
mutant APE1 proteins, support our hypothesis that lucanthone
docks at the hydrophobic site. Furthermore, another APE1
inhibitor study found that several potent APE1 inhibitors contain
two negatively charged ionizable groups separated by a hydro-
phobic core [57], features characteristic in lucanthone/hycan-
thone. As recently shown for the phenyl ring of the APE1
inhibitor, 6-hydroxy-DL-DOPA [55], the tri phenyl ring of
lucanthone could form a pi stacking interaction to Phe266. Since
our binding studies revealed that the Ka for hycanthone is about 8-
fold higher than lucanthone, additional interactions between the
former compound and the APE1 active site can be implied.
Indeed, molecular docking revealed that in addition to key non-
covalent van der Waals interactions seen with lucanthone, the
extra hydroxyl groups of hycanthone can hydrogen bond with
His309 and coordinate the APE1 bound magnesium cation. Our
experimental studies found that lucanthone exhibited a lesser
effect on the conformational status of the APE1 single hydropho-
bic site mutants F266A and F266C, and almost no effect on the
double hydrophobic mutant F266A/W280A, consistent with no
cleavage or significant effect on the endonuclease activity of these
mutants (Figure 12A and B). However, surprisingly, we did see
significant cleavage with W280S indicating that replacing the
tryptophan residue with a serine did not alter the lucanthone
induced cleavage. This is in stark contrast to the dramatic
inhibition observed when phenylalanine was replaced by an
alanine or cytosine, presumably reflecting lucanthone being able to
bind the phenylalanine residue at 266 (as well as leucine at 282).
Figure 9. Identification of an approximate lucanthone cleavage site in APE1. LC/MS/MS identification of APE1 fragment after treatment
with 100 mM of lucanthone for 2 h at 37uC. The data were analyzed with Inspect. A). Peptide aa64–73 analysis of 35.5 Kda (Sample 1) and 25 kDa
(Sample 3). B). Elution profile of peptide aa64–73 in sample 1 and 3. C). Peptide aa282–299 analysis of 35.5 Kda (Sample 1) and 25 kDa (Sample 3). D).
Peptide aa53–63 analysis of 35.5 Kda (Sample 1) and 25 kDa (Sample 3). B). Elution profile of peptide aa53–63 in sample 1 and 3.
doi:10.1371/journal.pone.0023679.g009
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Figure 10. Lucanthone, Hycanthone and CRT cause APE1 degradation. Mass spectroscopic (MALDI-TOF) analysis of APE1 in presence of
lucanthone and CRT as described in materials and methods. APE1 (100 mM) was treated with 100 mM lucanthone and CRT for 2 h and 24 h and
changes in its mass was determined as described in Materials & Methods.
doi:10.1371/journal.pone.0023679.g010
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Apparently F266 is the more critical residue involved in
lucanthone binding.
We used another APE1 specific inhibitor CRT0044876 as a
control, as it was modeled to bind to the hydrophobic site [13].
However, the effects of this inhibitor are unclear, as recent data on
CRT have shown that its specificity for APE1 is controversial [58–
60]. Nonetheless, in our cell system, CRT could inhibit APE1
protein at high concentrations (200 mM), as opposed to the
inhibition we observed by lucanthone at 50 mM. The MALDI
analysis also revealed clear degradation of APE1 in the presence of
100 mM lucanthone by 2 h, whereas at the same concentration,
CRT0044876 did not cause degradation of APE1 until 24 h.
These studies indicate that lucanthone and hycanthone are more
potent APE1 inhibitors than CRT0044876.
As lucanthone and hycanthone were first used as DNA
intercalators with good anti-tumor activity, another aspect of the
inhibition of APE1 endonuclease activity likely involves an
indirect effect. For instance, like the indirect effect seen for
lucanthone or IA-5 on Topoisomerase II [61], the lucanthone–
DNA intercalation may cause a distortion in DNA, leading to an
Figure 11. Lucanthone and hycanthone docks at hydrophobic site in APE1. A) The lowest energy pose of docked APE1/lucanthone (gray)
superposes with the structure of the complex post 30 ns of MD simulation with an r.m.s.d. of 1.8. A˚. B) docked APE1/hycanhone (gray) superposes
with the structure of this complex post 30 ns of molecular dynamics simulation with an r.m.s.d. of 1.7. A˚.
doi:10.1371/journal.pone.0023679.g011
Figure 12. Molecular Dynamics simulation of APE1-bound Lucanthone and Hycanthone. A: lucanthone (magenta sticks) binds in the
hydrophobic pocket of Ape1, represented by its solvent accessible surface. Ape1 interacts with lucanthone mainly via apolar contacts with W280, pi-
stacking with F266, and M270. Additionally, a hydrogen bond forms between the carbonyl oxygen and T268. B) Hycanthone (magenta sticks) binds in
the DNA groove/hydrophobic pocket of APE1. In addition to apolar contacts and pi-stacking with F266, it forms a hydrogen bond with His309 and
coordinates with the APE1-bound magnesium cation (represented as gray sphere).
doi:10.1371/journal.pone.0023679.g012
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Figure 13. Lucanthone does not alter conformation of double hydrophobic site APE1 mutant, human Nth and bacterial Nfo
proteins. CD spectra of APE1 and its mutants in presence of lucanthone. APE1- hydrophobic site mutant proteins F266A/C, F266A/W280A, active site
mutant D210N and non-related BSA protein or human Nth or E.coli Nfo(10 mg/ml), 50 ml (500 mg) (14 mM) in APE1 buffer (50 mM HEPES, 150 mM
KCl, 5 mM MgCl2), was mixed with lucanthone (1 mg/ml), 50 ml (50 mg) (140 mM), incubated at 37uC for 60 min and far UV-CD spectra with
specifications.
doi:10.1371/journal.pone.0023679.g013
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impaired recognition of an abasic site by APE1. However, it is
important to note that researchers have found no quantitative
correlation between the ability of thioxanthenones to bind DNA
and their antitumor ability [62], indicating that DNA interca-
lation is not sufficient for antitumor activity. These studies
therefore indicate an important role for other macromolecules
like proteins, such as DNA repair enzymes and accessory factors
like HMGB1, in the potency of these compounds. Since the
DNA binding ability of APE1 was only marginally altered by
lucanthone and not by hycanthone, our data indicate that the
effect of lucanthone is more likely due to its direct effect on the
enzymology of APE1. Although lucanthone induced cytotoxicity
has been attributed more to inhibition of Topo II [63], our
present study, along with the past biochemical and cellular
effects reported, indicate that APE1 is likely an important
biological target. We therefore believe that APE1 may be
developed as a biomarker for lucanthone-based treatment
efficacy and that these studies provide a molecular framework
for the design of more efficacious and clinically safe thiox-
anthenones.
Figure 14. Lucanthone causes cleavage of APE1 with intact hydrophobic site. (A). Western blot of recombinant and mutant APE1 proteins
(upper panel) treated with 100 mM lucanthone (lower panel) at 37uC for 2 h. (B). Endonuclease activity inhibition of wild type and F266A mutant of
APE1 in presence of 100 mM of lucanthone for 2 h at 37uC.
doi:10.1371/journal.pone.0023679.g014
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Supporting Information
Figure S1 Lucanthone (left) and Hycanthone (right). The
Molecular structure was generated with Marvin Sketch.
(TIF)
Figure S2 Lucanthone binding with APE1 reached
saturation at higher concentration. APE1 protein (100 mg)
(ligand) was immobilized on carboxymethyl-5 (CM-5) chip by
amine coupling according to manufacturer’s instructions. lucan-
thone (analyte) with higher concentration (20–1325 mM) was
tested for binding to APE1 on BAICORE 2000 SPR measurement
system available at SUNYSB proteomics core facility.
(TIF)
Figure S3 CD spectra of APE1 and its mutant W280S in
presence of lucanthone. APE1/W280 S (10 mg/ml), 50 ml
(500 mg) (14 mM) in APE1 buffer (50 mM HEPES, 150 mM KCl,
5 mM MgCl2), was mixed with lucanthone (1 mg/ml), 50 ml
(50 mg) (140 mM), incubated at 37uC for 60 min and far UV-CD
spectra with specifications taken as described previously.
(TIF)
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Figure 15. Lucanthone and Hycanthone do not significantly affect the DNA binding capacity of APE1. Gel mobility shift assay for
determining the effect of lucanthone and hycanthone on DNA binding capacity of APE1. APE1 at 10 nM and 25 nM was mixed with 100 mM
lucanthone or 100 mM hycanthone in the buffer that contained 50 mM HEPES, 150 mM KCl, 0.1 mg/ml BSA, 0.5 mM EDTA and 1 mM DTT. The
mixture was incubated at room temperature for 30 min. Subsequently, 10 nM radiolabeled substrate that contained an abasic site was added in the
mixture and incubated with the enzyme for additional 30 min to allow binding of APE1 to the substrate. 8 ml binding mixture was subject to
electrophoresis at 4uC, 100 V for 1.5 h in a 1% agarose–0.1% acrylamide gel. The gel was then dried on DE81 paper, and APE1-DNA complex was
detected by phosphorimager as described previously [52].
doi:10.1371/journal.pone.0023679.g015
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